Advertisement
BIIB or PRAX or REGN
Which Stock Would AI Choose? Biogen (BIIB) vs. Praxis Precision Medicines (PRAX) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- BIIB has shown resilience with approximately 30% gains over the past year, driven by advancements in Alzheimer's and ALS therapies, trading around $184 recently.
- PRAX delivered explosive growth exceeding 700% in the last year amid NDA filings for essential tremor and epilepsy treatments, though recent weeks saw volatility around $295.
- REGN maintains stability with about 18% annual appreciation, bolstered by Dupixent approvals, hovering near $742 in recent market activity.
- All three biotech firms focus on neurology and immunology, but PRAX leads in momentum while BIIB and REGN offer proven revenue streams.
- Recent performance reflects sector trends: PRAX down over recent weeks post-rally, BIIB steady, REGN slightly softer amid broader pressures.
- Investor interest centers on pipeline catalysts, with PRAX's multiple Phase 3 readouts positioning it for potential near-term upside.
Introduction
This stock comparison examines BIIB, PRAX, and REGN, all biotech leaders targeting central nervous system disorders, epilepsy, multiple sclerosis, and immunology. These companies appeal to traders seeking momentum from clinical milestones and investors favoring established revenue with growth potential. In the current market, where biotech sentiment hinges on regulatory progress and pipeline data, understanding their relative performance, business models, and recent catalysts provides key insights for portfolio positioning and stock comparison analysis.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) specializes in therapies for neurological diseases, including multiple sclerosis drugs like TECFIDERA and AVONEX, SPINRAZA for spinal muscular atrophy, and LEQEMBI for Alzheimer's in partnership with Eisai. Recent market activity has seen BIIB trading around $184, reflecting about 30% gains over the past year amid positive analyst updates and pipeline advancements. Sentiment has been influenced by long-term data on LEQEMBI persistence, Phase 3 studies in pediatric MS, and collaborations like zorevunersen with Stoke Therapeutics for Dravet syndrome. Q4 results beat estimates with FY26 guidance above consensus, supporting steady performance despite some recent weeks' dips, as the stock holds above its 52-week low of $110.
PRAX Overview and Recent Performance
Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharma developing precision therapies for CNS disorders via its Cerebrum small molecule and Solidus ASO platforms. Key candidates include ulixacaltamide for essential tremor and relutrigine for developmental epileptic encephalopathies, both under NDA review. The stock, around $295 lately, has surged over 700% in the past year on Breakthrough Therapy designations and a $575M offering extending its cash runway to $1.5B pro forma. Recent volatility stems from post-rally consolidation, with multiple 2026 topline readouts anticipated across Phase 3 trials for epilepsy and movement disorders, driving high trader interest in its relative performance.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals, Inc. (REGN) focuses on monoclonal antibodies and genetics-driven therapies, with blockbusters like EYLEA for eye diseases and Dupixent (partnered with Sanofi) for immunology. Trading near $742 in recent sessions, REGN has risen about 18% over the past year, underpinned by Dupixent expansions including Japan approval for bullous pemphigoid. Market sentiment reflects Q4 beats and ongoing oncology/eye care progress, though recent weeks showed mild pressure amid sector rotation, with the stock above its 52-week low of $476 but below the high of $821.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies. These bots employ advanced Financial Learning Models for pattern recognition, achieving standout stats like up to 171% annualized 30-day returns, 90-100% win rates on select agents, and gains exceeding 279% in high-frequency ETF plays. Timeframes range from 5-minute scalps to swing trades, with performances varying by sector—e.g., 192% in aerospace or 159% on leveraged tech ETFs. Only bots demonstrating superior adaptation to current volatility and market conditions earn trending status. Traders can explore these for copy trading opportunities tailored to biotech momentum like BIIB, PRAX, and REGN. Visit Trending AI Robots to review live stats and deploy suitable agents.
Head-to-Head Comparison
BIIB, PRAX, and REGN share neurology exposure but diverge in scale and stage. REGN's diversified model yields robust revenue from Dupixent and EYLEA, contrasting BIIB's MS/Alzheimer's focus amid biosimilar risks. PRAX, pre-revenue, bets on genetic epilepsies with higher growth drivers via NDAs but elevated clinical risks. Recent momentum favors PRAX's rally, while BIIB edges stability over REGN's recent softness. Valuation sensitivity is acute for PRAX (sky-high post-surge), versus REGN's premium P/E on earnings power. Market sentiment tilts toward catalysts: PRAX for approvals, BIIB/ REGN for expansions.
Tickeron AI Verdict
Tickeron’s AI currently favors PRAX for its superior trend consistency and catalyst density, including NDA progress and Phase 3 momentum, positioning it strongly relative to BIIB's steadiness and REGN's scale. Observable factors like 700%+ annual gains and extended runway suggest higher probabilistic upside, though with volatility trade-offs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 1 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s), and REGN’s FA Score reflects 2 green FA rating(s).
- BIIB’s FA Score: 1 green, 4 red.
- PRAX’s FA Score: 0 green, 5 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 5 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 5 bearish.
- PRAX’s TA Score: 5 bullish, 4 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +3.95% price change this week, while PRAX (@Biotechnology) price change was +8.34% , and REGN (@Biotechnology) price fluctuated +0.40% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.06%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was +7.76%.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.37%. For the same industry, the average monthly price growth was +12.35%, and the average quarterly price growth was +11.73%.
Reported Earning Dates
BIIB is expected to report earnings on Apr 29, 2026.
PRAX is expected to report earnings on May 13, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+2.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+6.37% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | PRAX | REGN | |
| Capitalization | 26.9B | 9.53B | 79.2B |
| EBITDA | 2.6B | -326.06M | 5.82B |
| Gain YTD | 4.176 | 16.045 | -2.793 |
| P/E Ratio | 20.86 | N/A | 18.07 |
| Revenue | 9.89B | 0 | 14.3B |
| Total Cash | 3.82B | 599M | 8.61B |
| Total Debt | 6.58B | 110K | 2.71B |
BIIB | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 75 | |
SMR RATING 1..100 | 78 | 54 | |
PRICE GROWTH RATING 1..100 | 47 | 26 | |
P/E GROWTH RATING 1..100 | 13 | 40 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for BIIB (90). This means that REGN’s stock grew significantly faster than BIIB’s over the last 12 months.
REGN's Profit vs Risk Rating (75) in the Biotechnology industry is in the same range as BIIB (100). This means that REGN’s stock grew similarly to BIIB’s over the last 12 months.
REGN's SMR Rating (54) in the Biotechnology industry is in the same range as BIIB (78). This means that REGN’s stock grew similarly to BIIB’s over the last 12 months.
REGN's Price Growth Rating (26) in the Biotechnology industry is in the same range as BIIB (47). This means that REGN’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is in the same range as REGN (40). This means that BIIB’s stock grew similarly to REGN’s over the last 12 months.
| BIIB | PRAX | REGN | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 65% | 4 days ago 90% | 4 days ago 75% |
| Momentum ODDS (%) | 1 day ago 57% | 4 days ago 90% | 4 days ago 52% |
| MACD ODDS (%) | 1 day ago 55% | 4 days ago 90% | 4 days ago 49% |
| TrendWeek ODDS (%) | 1 day ago 58% | 4 days ago 86% | 4 days ago 66% |
| TrendMonth ODDS (%) | 1 day ago 58% | 4 days ago 88% | 4 days ago 60% |
| Advances ODDS (%) | 1 day ago 57% | 7 days ago 84% | 20 days ago 64% |
| Declines ODDS (%) | 11 days ago 72% | 5 days ago 84% | 5 days ago 51% |
| BollingerBands ODDS (%) | 1 day ago 48% | 4 days ago 86% | 4 days ago 49% |
| Aroon ODDS (%) | 1 day ago 64% | 4 days ago 86% | 4 days ago 70% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BUCK | 23.63 | 0.01 | +0.03% |
| Simplify Treasury Option Income ETF | |||
| SJCP | 24.94 | N/A | N/A |
| SanJac Alpha Core Plus Bond ETF | |||
| IFEB | 30.93 | -0.05 | -0.16% |
| Innovator Intl Dev Pwr Bffr ETF - Feb | |||
| XYLD | 39.88 | -0.07 | -0.17% |
| Global X S&P 500® Covered Call ETF | |||
| ICPY | 11.92 | -0.09 | -0.75% |
| Tweedy, Browne International Ins+Val ETF | |||
PRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To PRAX | 1D Price Change % | ||
|---|---|---|---|---|
| PRAX | 100% | -0.14% | ||
| BEAM - PRAX | 40% Loosely correlated | -0.45% | ||
| BHVN - PRAX | 37% Loosely correlated | -1.46% | ||
| RAPP - PRAX | 35% Loosely correlated | -6.35% | ||
| VERU - PRAX | 35% Loosely correlated | -0.41% | ||
| RXRX - PRAX | 35% Loosely correlated | -2.38% | ||
More | ||||